148 related articles for article (PubMed ID: 23278160)
1. A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p.
Namberger K; Weiss L; Krause B; Melchardt T; Greil R
Eur J Haematol; 2013 Apr; 90(4):349-50. PubMed ID: 23278160
[No Abstract] [Full Text] [Related]
2. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
Strati P; Keating MJ; O'Brien SM; Ferrajoli A; Burger J; Faderl S; Tambaro FP; Jain N; Wierda WG
Haematologica; 2014 Aug; 99(8):1350-5. PubMed ID: 24859876
[TBL] [Abstract][Full Text] [Related]
3. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.
Stilgenbauer S; Döhner H
N Engl J Med; 2002 Aug; 347(6):452-3. PubMed ID: 12167696
[No Abstract] [Full Text] [Related]
4. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
Lacerda MP; Guedes NR; Yamakawa PE; Pereira AD; Fonseca ARBMD; Chauffaille MLLF; Goncalves MV; Yamamoto M; Rodrigues CA
Ann Hematol; 2017 Sep; 96(9):1577-1578. PubMed ID: 28597168
[No Abstract] [Full Text] [Related]
5. Chronic lymphocytic leukemia (CLL): first-line treatment.
Hallek M;
Hematology Am Soc Hematol Educ Program; 2005; ():285-91. PubMed ID: 16304393
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed chronic lymphocytic leukemia after venetoclax.
Thompson MC; Mato AR
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):18-23. PubMed ID: 33275734
[No Abstract] [Full Text] [Related]
7. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
9. Novel agents in chronic lymphocytic leukemia.
Lamanna N; O'Brien S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):137-145. PubMed ID: 27913472
[TBL] [Abstract][Full Text] [Related]
10. Safety profiles of novel agent therapies in CLL.
Ahn IE; Davids MS
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):354-357. PubMed ID: 29222278
[TBL] [Abstract][Full Text] [Related]
11. Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia.
Lamanna N; Weiss MA
Curr Oncol Rep; 2008 Sep; 10(5):363-4. PubMed ID: 18706262
[No Abstract] [Full Text] [Related]
12. Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.
Kuss BJ; Tam CS
Intern Med J; 2017 Dec; 47 Suppl 6():5-10. PubMed ID: 29250930
[TBL] [Abstract][Full Text] [Related]
13. Sequencing of chronic lymphocytic leukemia therapies.
Barrientos JC
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):128-136. PubMed ID: 27913471
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected].
Arnason JE; Brown JR
Hematology Am Soc Hematol Educ Program; 2011; 2011():119-20. PubMed ID: 22160022
[TBL] [Abstract][Full Text] [Related]
15. Chronic lymphocytic leukaemia--moving towards cure?
Hillmen P
Lancet; 2010 Oct; 376(9747):1122-4. PubMed ID: 20888976
[No Abstract] [Full Text] [Related]
16. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Flinn IW; Hillmen P; Montillo M; Nagy Z; Illés Á; Etienne G; Delgado J; Kuss BJ; Tam CS; Gasztonyi Z; Offner F; Lunin S; Bosch F; Davids MS; Lamanna N; Jaeger U; Ghia P; Cymbalista F; Portell CA; Skarbnik AP; Cashen AF; Weaver DT; Kelly VM; Turnbull B; Stilgenbauer S
Blood; 2018 Dec; 132(23):2446-2455. PubMed ID: 30287523
[TBL] [Abstract][Full Text] [Related]
17. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
[TBL] [Abstract][Full Text] [Related]
18. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
19. 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.
Schnaiter A; Stilgenbauer S
Hematol Oncol Clin North Am; 2013 Apr; 27(2):289-301. PubMed ID: 23561474
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.
Shimada K; Tomita A; Saito S; Kiyoi H
Br J Haematol; 2014 Aug; 166(3):455-7. PubMed ID: 24673649
[No Abstract] [Full Text] [Related]
[Next] [New Search]
